Pulmatrix, Inc. PULM
Set alert
As of Nov 2, 10:57 AM ET
- YTD
- -38.57%
- 1 year
- -72.21%
- Open
- 1.41
- Prev close
- 1.42
- Mkt cap
- 5.19M
- Vol
- 611
- Avg vol
- 26.50K
- EPS
- -1.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.42
- High
- 1.42
- Forward P/E
- -1.28
- Beta
- 0.99
- Short ratio
- 0.75
- Inst. own
- 7.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.18
- 200-d avg
- 2.54
- 1y target
- 0.00
News
3 days ago globenewswire.com
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support…
-
1 week ago benzinga.com
Eos SENOLYTIX Presents New Preclinical Survival, Healthspan, Mechanism-Of-Action Data For Its PTC-2105 Candidate At 17th World Congress On Targeting Mitochondria 2026
Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and
1 week ago globenewswire.com
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)…
1 week ago defenseworld.net
Pulmatrix (NASDAQ:PULM) Share Price Breaks Below Fifty Day Moving Average – Here’s What Happened
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) shares crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.50 and traded as low as…
1 month ago defenseworld.net
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 55,391 shares, an…
-
1 month ago benzinga.com
Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity
Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and is conducting IND-enabling studies to support the initiation of first-in-human clinical trials,…
-
1 month ago benzinga.com
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4
Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and
1 month ago globenewswire.com
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward…
-
2 months ago benzinga.com
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.
2 months ago prnewswire.com
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a…
3 months ago gurufocus.com
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN PR Newswire
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
5 months ago gurufocus.com
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix Announces First Quarter 2026 Financial Results PR Newswire FRAMINGHAM, Mass., May 15, 2026
-
5 months ago benzinga.com
Pulmatrix Q1 EPS $(0.32) Up From $(0.50) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.32) per share. This is a 36 percent increase over losses of $(0.50) per share from the same period last year.
5 months ago prnewswire.com
Pulmatrix Announces First Quarter 2026 Financial Results
Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company")…
6 months ago prnewswire.com
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc.…
6 months ago businesswire.com
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Eos SENOLYTIX, Inc. Upon closing of the proposed…
6 months ago defenseworld.net
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) shares passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.15 and traded as low as $1.18.…
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
7 months ago benzinga.com
Pulmatrix Signs Agreement To Acquire Eos SENOLYTIX; Financial Terms Undisclosed
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related…
7 months ago prnewswire.com
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related…
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
8 months ago prnewswire.com
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger…
-
8 months ago benzinga.com
Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.25) per share. This is a 54.55 percent increase over losses of $(0.55) per share from the same period last year.
8 months ago prnewswire.com
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a…
8 months ago defenseworld.net
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next?
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.71 and traded as low as…
9 months ago defenseworld.net
INmune Bio (NASDAQ:INMB) & Pulmatrix (NASDAQ:PULM) Head-To-Head Review
Pulmatrix (NASDAQ: PULM - Get Free Report) and INmune Bio (NASDAQ: INMB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
10 months ago prnewswire.com
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass. , Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc.…
11 months ago defenseworld.net
Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $4.75 and traded as…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule…
-
1 year ago benzinga.com
Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.
1 year ago prnewswire.com
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.
-
1 year ago benzinga.com
Pulmatrix Seeks Divestment Of Clinical Assets And iSPERSE Inhalation Technology Amid Advancements In Migraine, COPD, And Antifungal Treatments
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE™ TechnologyiSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix And Cullgen Announce Proposed Merger; Pre-Merger Pulmatrix Stockholers To Own ~3.6% Of Combined Company; Pre-Merger Cullgen Stockholders To Own ~96.4% Of Combined Company Under Name Cullgen
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of…
-
1 year ago benzinga.com
Pulmatrix Q3 EPS $(0.71) Up From $(1.03) YoY, Sales $366.00K Down From $1.75M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.71) per share. This is a 31.07 percent increase over losses of $(1.03) per share from the same period last year. The company reported $366.00…
-
2 years ago benzinga.com
Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE.Self-administered PUR3100 showed…
-
2 years ago benzinga.com
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by 45.19 percent. This is a 50 percent increase over losses of $(1.14) per…
-
2 years ago benzinga.com
Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix…
-
2 years ago benzinga.com
Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Estimate, Sales $1.75M Miss $1.86M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by 1.9 percent. This is a 28.97 percent increase over losses of $(1.45) per…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine